Shi Qin, Zhang Zihan, Zhang Wen, Ma Jingqin, Yang Minjie, Luo Jianjun, Liu Lingxiao, Yan Zhiping
Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Shanghai Institution of Medical Imaging, Shanghai, 200032, China.
J Interv Med. 2023 Jul 16;6(3):121-125. doi: 10.1016/j.jimed.2023.07.002. eCollection 2023 Aug.
To determine the safety and efficacy of microwave ablation (MWA) and transarterial chemoembolization (TACE) with doxorubicin hydrochloride liposome (DHL) in patients with primary liver cancer (PLC) and metastatic liver cancer (MLC).
The medical records of patients with primary or metastatic liver cancer who underwent MWA combined with TACE containing DHL from March 2019 to March 2022 were collected and analyzed. Treatment-related adverse events (AEs) were recorded. Local tumor response was evaluated according to the modified RECIST criteria. Local tumor progression-free survival (LTPFS) and overall survival (OS) were calculated using the Kaplan-Meier method.
Altogether, 96 patients with liver cancer were included (PLC, n = 45; MLC, n = 51). Forty (41.7%) patients experienced AEs during treatment, and eight (8.3%) patients developed grade 3 AEs. Compared to before treatment, the serum total bilirubin level and neutrophil to lymphocyte ratio significantly increased after treatment. The median LTPFS was 14.5 months in patients with PLC and 10.7 months in patients with MLC. The median OS was not reached in patients with PLC or MLC. The 1-month and 3-month disease control rates reached more than 80% in both groups.
MWA combined with TACE with DHL may be a safe and effective method for the treatment of liver cancer.
确定微波消融（MWA）联合盐酸阿霉素脂质体（DHL）经动脉化疗栓塞术（TACE）治疗原发性肝癌（PLC）和转移性肝癌（MLC）患者的安全性和有效性。
收集并分析2019年3月至2022年3月期间接受MWA联合含DHL的TACE治疗的原发性或转移性肝癌患者的病历。记录与治疗相关的不良事件（AE）。根据改良的RECIST标准评估局部肿瘤反应。采用Kaplan-Meier法计算局部无肿瘤进展生存期（LTPFS）和总生存期（OS）。
共纳入96例肝癌患者（PLC，n = 45；MLC，n = 51）。40例（41.7%）患者在治疗期间出现AE，8例（8.3%）患者发生3级AE。与治疗前相比，治疗后血清总胆红素水平和中性粒细胞与淋巴细胞比值显著升高。PLC患者的中位LTPFS为14.5个月，MLC患者为10.7个月。PLC或MLC患者的中位OS均未达到。两组的1个月和3个月疾病控制率均超过80%。
MWA联合含DHL的TACE可能是一种治疗肝癌的安全有效的方法。
